Dutasteride vs PTD-DBM
A side-by-side research comparison of Dutasteride and PTD-DBM across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dutasteride | PTD-DBM |
|---|---|---|
| Full name | Dutasteride (Avodart) | PTD-DBM (Wnt Pathway Hair Peptide) |
| Category | Hair Growth | Hair Growth |
| Status | FDA Approved (BPH) / Off-label hair loss | Research peptide (topical) |
| Mechanism | Inhibits both type I and type II 5-alpha reductase isoenzymes, reducing serum DHT by ~90% and scalp DHT by ~50%. Prevents miniaturization of androgen-sensitive hair follicles in the vertex and frontal scalp. | PTD-DBM disrupts the interaction between CXXC5 and Dishevelled, releasing a natural brake on the Wnt/beta-catenin signaling pathway. Enhanced Wnt signaling promotes hair follicle neogenesis and regeneration. |
| Molecular weight | 528.53 Da | ~ (short cell-penetrating peptide) |
| Half-life | ~5 weeks (extremely long) | Topical (local action) |
| Bioavailability | ~60% oral | Topical (local delivery) |
| Typical dose | 0.5 mg | Topical scalp application (research) |
| Frequency | Daily | Daily |
| Route | Oral capsule | Topical |
Dutasteride reported benefits
- Superior DHT suppression vs finasteride
- Hair regrowth and thickening
- Reduced hair miniaturization
- Prostate volume reduction
- Effective for diffuse thinning
PTD-DBM reported benefits
- Activates Wnt/beta-catenin hair pathway
- Promotes follicle neogenesis (research)
- Synergy with valproic acid
- Non-hormonal hair mechanism
Related comparisons
Research and educational reference only. Not medical advice.